1-3 of 3
Fabien Lebras
Close
Sort by
Journal Articles

Overview of the French Practice: Therapeutic Strategies in Patient's First Relapse or Refractory Non IgM AL Amyloidosis

Camille Villesuzanne, Stephanie Harel, Alexis Talbot, MD, Bruno Royer, MD, Naelle Lombion, Fabien Lebras, MD, Mathilde Nouvier, MD, Arnaud Jaccard, MD PhD, Bertrand Arnulf
Journal: Blood
Blood (2018) 132 (Supplement 1): 3297.
https://doi.org/10.1182/blood-2018-99-114834
Published: 2018
Journal Articles

Risk of AML Evolution In Lower Risk MDS with Del 5q Treated with or without Lenalidomide. A Report by the Groupe Francophone Des Myelodysplasies (GFM)

Lionel Ades, Fabien Lebras, Marie Sebert, Charikleia Kelaidi, Thierry Lamy, Francois Dreyfus, Jacques Delaunay, Sorin Visanica, Pascal Turlure, MD, Agnes Guerci, Marie Paule Cabrol, Anne Banos, Michel Blanc, Norbert Vey, Virginie Eclache, Sylvie Chevret, Pierre Fenaux
Journal: Blood
Blood (2010) 116 (21): 976.
https://doi.org/10.1182/blood.V116.21.976.976
Published: 2010
Journal Articles

Treatment of Lower Risk MDS with Del 5q by Lenalidomide, with or without G-CSF: Current Results of the French Patient Named Program (ATU)

Fabien Lebras, Marie Sebert, Virginie Eclache, Thierry Lamy, Jacques Delaunay, Sorin Visanica, Francois Dreyfus, Anne Banos, Michel Blanc, Caroline Besson, Xavier Thomas, Philippe Rodon, Norbert Vey, Martine Gardembas, Frederic Bauduer, MD, Jean-Francois Ramee, Alain Delmer, Delphine Rea, Pascal Turlure, Odile Beyne-Rauzy, Agnes Guerci, Joel Ceccaldi, J. Dugay, Pierre Fenaux, Lionel Ades
Journal: Blood
Blood (2008) 112 (11): 5069.
https://doi.org/10.1182/blood.V112.11.5069.5069
Published: 2008